Efficacy and cost-effectiveness of Collatamp-G for infection prophylaxis in cardiac surgery
Pan I, Dendukuri N, McGregor M
Record ID 32010000175
English
Authors' recommendations:
The available evidence suggests that GCS may well reduce the incidence of SWI, particularly of superficial infections. Initial estimates indicate that GCS might be used for all cardiac patients at the MUHC at a gross cost of $716,470 and if the health benefits are fully realised, a net cost of approximately $225,460 per annum. However, the available evidence is not sufficiently substantial for the development of a permanent ongoing policy.
Details
Project Status:
Completed
URL for project:
http://www.mcgill.ca/files/tau/COLLATAMP_CARDIAC_REPORT.pdf
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Anti-Bacterial Agents
- Cardiovascular Surgical Procedures
- Collagen
- Costs and Cost Analysis
- Tissue Adhesives
Contact
Organisation Name:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
Contact Address:
Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5
Contact Name:
nandini.dendukuri@mcgill.ca
Contact Email:
nandini.dendukuri@mcgill.ca
Copyright:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.